Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akari Therapeutics PlcAKTX · Entity 7692 | Director · CEO | September 29, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akari Therapeutics Plc
Report date September 29, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary Shares representing Ordinary SharesSEC Table I · non-derivative | Direct | 14,107 |
Reported balance
After 2026-09-29 transaction · row 1
1 source rowRow 1 · 2026-09-29 · Grant · Acquired 6,430 · Balance 14,107 F1: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. RSUs were granted on September 29, 2026 and vest in four approximately equal quarterly installments on November 18, 2026, February 18, 2027, May 18, 2027, and August 18, 2027, subject to continued service. The RSUs are subject to forfeiture and cancellation if the Issuer's shareholders do not approve an amendment to the Issuer's equity incentive plan increasing the number of shares reserved for issuance under the plan. |
Filing footnotes · ownership attribution and instrument terms
F1: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. RSUs were granted on September 29, 2026 and vest in four approximately equal quarterly installments on November 18, 2026, February 18, 2027, May 18, 2027, and August 18, 2027, subject to continued service. The RSUs are subject to forfeiture and cancellation if the Issuer's shareholders do not approve an amendment to the Issuer's equity incentive plan increasing the number of shares reserved for issuance under the plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 29, 2026 Filed Oct 2, 2026 00:50 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 6,430 | $9.72 | $62,499.60 |
DisclosureSEC source: 0001493152-26-045366 · ownership.xml · nonDerivative · entry 1 Gaslightwala Abizer · CIK 0002049375 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,107 F1 · shares: These American Depositary Shares represent restricted stock units ("RSUs"), with each such RSU representing the right to receive 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. RSUs were granted on September 29, 2026 and vest in four approximately equal quarterly installments on November 18, 2026, February 18, 2027, May 18, 2027, and August 18, 2027, subject to continued service. The RSUs are subject to forfeiture and cancellation if the Issuer's shareholders do not approve an amendment to the Issuer's equity incentive plan increasing the number of shares reserved for issuance under the plan. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 00:04 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantStock Option (Right to Buy) · Derivative | 15,563 | $0.00 Strike: $14.63 | $0.00 |
DisclosureSEC source: 0001493152-26-030207 · ownership.xml · derivative · entry 2 Gaslightwala Abizer · CIK 0002049375 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,563 Underlying: American Depositary Shares representing Ordinary Shares · 15,563 shares Expires 2036-06-24 Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 00:04 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantStock Option (Right to Buy) · Derivative | 5,500 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001493152-26-030207 · ownership.xml · derivative · entry 1 Gaslightwala Abizer · CIK 0002049375 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: American Depositary Shares representing Ordinary Shares · 5,500 shares Expires 2036-04-01 F1 · balance_after: On April 1, 2026, the reporting person was granted an option to purchase 15,000 American Depositary Shares, with each American Depositary Share representing 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The option vests in three installments based on the closing of qualified financings of at least $15,000,000 in gross proceeds on or before June 30, 2026. The Issuer closed a qualified financing of $5,500,000, resulting in the vesting of the option as to 5,500 American Depositary Shares. Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 02:56 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchasePre-Funded Warrants to purchase ADRs · Derivative | 773,323 | $0.40 Strike: $0.00 | $312,499.82 |
DisclosureSEC source: 0001493152-25-028417 · ownership.xml · derivative · entry 4 Gaslightwala Abizer · CIK 0002049375 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 773,323 Underlying: American Depositary Shares representing Ordinary Shares · 773,323 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F5 · security: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 773,323 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 804,790 ADSs (the "Note Exchange Unregistered Warrants"). F7 · derivative.exercise_price: Conversion Exercise Price of Security is $0.00001 F5 · price: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 773,323 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 804,790 ADSs (the "Note Exchange Unregistered Warrants"). F6 · derivative.exercise_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. F6 · derivative.expiration_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 02:56 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchaseWarrants to purchase ADRs · Derivative | 773,323 | Not disclosed Strike: $0.39 | Not disclosed |
DisclosureSEC source: 0001493152-25-028417 · ownership.xml · derivative · entry 3 Gaslightwala Abizer · CIK 0002049375 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 773,323 Underlying: American Depositary Shares representing Ordinary Shares · 773,323 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F5 · security: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 773,323 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 804,790 ADSs (the "Note Exchange Unregistered Warrants"). F5 · price: On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) unregistered pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 773,323 ADSs, at a purchase price of $0.4041 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) unregistered warrants to purchase up to 804,790 ADSs (the "Note Exchange Unregistered Warrants"). F6 · derivative.exercise_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. F6 · derivative.expiration_date: The Note Exchange Unregistered Warrants and the Note Exchange Unregistered Pre-Funded Warrants shall be exercisable upon shareholder approval, with the Note Exchange Unregistered Warrants having a five-year term from such approval, and the Note Exchange Unregistered Pre-Funded Warrants remaining exercisable until fully exercised. Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 02:56 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchasePre-Funded Warrants to purchase ADRs · Derivative | 309,328 | $0.40 Strike: $0.00 | $124,999.44 |
DisclosureSEC source: 0001493152-25-028417 · ownership.xml · derivative · entry 2 Gaslightwala Abizer · CIK 0002049375 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 309,328 Underlying: American Depositary Shares representing Ordinary Shares · 309,328 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2 · security: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 309,328 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 309,328 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F7 · derivative.exercise_price: Conversion Exercise Price of Security is $0.00001 F4 · price: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3 · derivative.exercise_date: The Series G Warrants and the PIPE PFW shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. F3 · derivative.expiration_date: The Series G Warrants and the PIPE PFW shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 02:56 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchaseWarrants to purchase American Depositary Shares ("ADRs") · Derivative | 309,328 | Not disclosed Strike: $0.39 | Not disclosed |
DisclosureSEC source: 0001493152-25-028417 · ownership.xml · derivative · entry 1 Gaslightwala Abizer · CIK 0002049375 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 309,328 Underlying: American Depositary Shares representing Ordinary Shares · 309,328 shares Expires not disclosed F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.000000005 per Ordinary Share of the Issuer. F2 · security: On December 16, 2025, the Reporting Person acquired (i) unregistered pre-funded warrants to purchase up to 309,328 ADSs (the "PIPE PFWs" and ) and (ii) accompanying Series G Warrants to purchase up to 309,328 ADSs (the "Series G Warrants"), at a combined purchase price of $0.4041 per PIPE PFW and Series G Warrant in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended. F4 · price: The combined purchase price per one PIPE PFW and accompanying PIPE Series G Warrant was $0.4041. F3 · derivative.exercise_date: The Series G Warrants and the PIPE PFW shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. F3 · derivative.expiration_date: The Series G Warrants and the PIPE PFW shall be exercisable upon shareholder approval, with the Series G Warrants having a five-year term from such approval, and the PIPE PFWs remaining exercisable until fully exercised. Read SEC document |
| August 25, 2025 Filed Aug 29, 2025 20:55 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchaseAmerican Depositary Shares representing Ordinary Shares | 3,000 | $0.90 | $2,700.00 |
DisclosureSEC source: 0001641172-25-026025 · ownership.xml · nonDerivative · entry 3 Gaslightwala Abizer · CIK 0002049375 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298,574 F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. F4 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.89 to $0.90, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote. Read SEC document |
| August 22, 2025 Filed Aug 29, 2025 20:55 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchaseAmerican Depositary Shares representing Ordinary Shares | 8,000 | $0.93 | $7,440.00 |
DisclosureSEC source: 0001641172-25-026025 · ownership.xml · nonDerivative · entry 2 Gaslightwala Abizer · CIK 0002049375 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,574 F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. F3 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.92 to $0.93, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote. Read SEC document |
| August 21, 2025 Filed Aug 29, 2025 20:55 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchaseAmerican Depositary Shares representing Ordinary Shares | 10,000 | $0.94 | $9,400.00 |
DisclosureSEC source: 0001641172-25-026025 · ownership.xml · nonDerivative · entry 1 Gaslightwala Abizer · CIK 0002049375 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,574 F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.93 to $0.94, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote. Read SEC document |
| June 24, 2025 Filed Jun 25, 2025 20:30 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchaseAmerican Depositary Shares representing Ordinary Shares | 5,203 | $1.16 | $6,035.48 |
DisclosureSEC source: 0000950170-25-089976 · ownership.xml · nonDerivative · entry 2 Gaslightwala Abizer · CIK 0002049375 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,574 F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. F2 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within ranges set forth in this footnote. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 20:30 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchaseAmerican Depositary Shares representing Ordinary Shares | 943 | $1.15 | $1,084.45 |
DisclosureSEC source: 0000950170-25-089976 · ownership.xml · nonDerivative · entry 1 Gaslightwala Abizer · CIK 0002049375 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 272,371 F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 20:30 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchaseAmerican Depositary Shares representing Ordinary Shares | 10,000 | $1.20 | $12,000.00 |
DisclosureSEC source: 0000950170-25-089462 · ownership.xml · nonDerivative · entry 1 Gaslightwala Abizer · CIK 0002049375 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,428 F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 20:05 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | PurchaseAmerican Depositary Shares representing Ordinary Shares | 15,000 | $1.20 | $18,000.00 |
DisclosureSEC source: 0000950170-25-088490 · ownership.xml · nonDerivative · entry 1 Gaslightwala Abizer · CIK 0002049375 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,428 F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 25,000 | $1.19 | $29,750.00 |
DisclosureSEC source: 0000950170-25-086829 · ownership.xml · nonDerivative · entry 2 Gaslightwala Abizer · CIK 0002049375 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,428 F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. F3 · kind: On June 13, 2025, the Reporting Person acquired 10,000 ADS at an average price of $1.19 per ADS. F3 · price: On June 13, 2025, the Reporting Person acquired 10,000 ADS at an average price of $1.19 per ADS. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 20,000 | $1.23 | $24,600.00 |
DisclosureSEC source: 0000950170-25-086829 · ownership.xml · nonDerivative · entry 1 Gaslightwala Abizer · CIK 0002049375 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,428 F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. F2 · kind: On June 12, 2025, the Reporting Person acquired 20,000 ADS at an average price of $1.23 per ADS. F2 · price: On June 12, 2025, the Reporting Person acquired 20,000 ADS at an average price of $1.23 per ADS. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:30 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 20,000 | $1.27 | $25,400.00 |
DisclosureSEC source: 0000950170-25-085472 · ownership.xml · nonDerivative · entry 1 Gaslightwala Abizer · CIK 0002049375 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,428 F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. F2 · kind: On June 10, 2025, the Reporting Person acquired 20,000 ADS at an average price of $1.27 per ADS. F2 · price: On June 10, 2025, the Reporting Person acquired 20,000 ADS at an average price of $1.27 per ADS. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantStock Option (Right to Buy) · Derivative | 600,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000950170-25-043933 · ownership.xml · derivative · entry 3 Gaslightwala Abizer · CIK 0002049375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 Underlying: American Depositary Shares representing Ordinary Shares · 600,000 shares Expires 2035-03-20 F3 · derivative.exercise_date: The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock options shall vest upon achievement of at least one of the following performance criteria: either (a) closing of a qualified financing of at least $15,000,000 in gross proceeds on or before December 31, 2025, or (b) closing of an antibody drug conjugate ("ADC") focused license transaction, with a minimum upfront payment of $10,000,000 on or before December 31, 2025. If neither of these criteria are met by December 31, 2025 the performance-based option will expire. The stock option award is subject to continued service with the Issuer. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantStock Option (Right to Buy) · Derivative | 1,100,000 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0000950170-25-043933 · ownership.xml · derivative · entry 2 Gaslightwala Abizer · CIK 0002049375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100,000 Underlying: American Depositary Shares representing Ordinary Shares · 1,100,000 shares Expires 2035-03-20 F2 · derivative.exercise_date: The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. The stock option shall vest over four years from the grant date with 25% vesting on the 12 month anniversary of the grant date, and the remainder vesting ratably on a monthly basis over the then remaining 36 months from the grant date, such that it will be fully vested on the fourth anniversary of the grant date. The stock option award is subject to continued service with the Issuer. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantSeries B Warrants (Right to Buy) · Derivative | 133,928 | $1.12 Strike: $0.87 | $149,999.36 |
DisclosureSEC source: 0000950170-25-036483 · ownership.xml · derivative · entry 3 Gaslightwala Abizer · CIK 0002049375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,928 Underlying: American Depositary Shares representing Ordinary Shares · 133,928 shares Expires 2030-03-06 F2 · kind: On March 6, 2025, the Reporting Person acquired 133,928 ADS and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F2 · price: On March 6, 2025, the Reporting Person acquired 133,928 ADS and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantSeries A Warrants (Right to Buy) · Derivative | 133,928 | $1.12 Strike: $0.87 | $149,999.36 |
DisclosureSEC source: 0000950170-25-036483 · ownership.xml · derivative · entry 2 Gaslightwala Abizer · CIK 0002049375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,928 Underlying: American Depositary Shares representing Ordinary Shares · 133,928 shares Expires 2026-03-06 F2 · kind: On March 6, 2025, the Reporting Person acquired 133,928 ADS and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F2 · price: On March 6, 2025, the Reporting Person acquired 133,928 ADS and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F1 · derivative.underlying: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 21:00 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depositary Shares representing Ordinary Shares | 133,928 | $1.12 | $149,999.36 |
DisclosureSEC source: 0000950170-25-036483 · ownership.xml · nonDerivative · entry 1 Gaslightwala Abizer · CIK 0002049375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,428 F1 · security: Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. F2 · kind: On March 6, 2025, the Reporting Person acquired 133,928 ADS and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. F2 · price: On March 6, 2025, the Reporting Person acquired 133,928 ADS and accompanying Series A and Series B warrants to purchase up to 267,856 ADS in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of February 27, 2025. The combined purchase price was $1.12 per ADS and accompanying Series A and Series B warrant. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 13:05 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depository Shares representing Ordinary Shares | 11,439 | $1.22 | $13,955.58 |
DisclosureSEC source: 0000950170-25-004580 · ownership.xml · nonDerivative · entry 1 Gaslightwala Abizer · CIK 0002049375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,860 F1 · security: Each American Depository Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. F2 · kind: On January 10, 2025, the Reporting Person acquired 11,439 ADS at purchase price of $1.22 per ADS. F2 · price: On January 10, 2025, the Reporting Person acquired 11,439 ADS at purchase price of $1.22 per ADS. Read SEC document |
| January 10, 2025 Filed Feb 7, 2025 21:30 UTC Amendment | Akari Therapeutics Plc AKTX · Entity 7692 | GrantAmerican Depository Shares representing Ordinary Shares | 11,640 | $1.22 | $14,200.80 |
DisclosureSEC source: 0000950170-25-016334 · ownership.xml · nonDerivative · entry 1 Gaslightwala Abizer · CIK 0002049375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,500 F1 · security: Each American Depository Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. F2 · kind: On January 13, 2025, the Reporting Person previously reported the purchase of 11,439 ADS at purchase price of $1.22 per ADS. The Reporting Person actually acquired 11,640 ADS at a price raning from $1.22 per ADS to $1.28 per ADS. The Reporting Person also previously reported the total amount of securities beneficially owned following transaction as 35,860 and omitted the ADS acquired on January 10, 2025. The revised amount of securities beneficially owned following the transaction is 47,500 ADS. F2 · price: On January 13, 2025, the Reporting Person previously reported the purchase of 11,439 ADS at purchase price of $1.22 per ADS. The Reporting Person actually acquired 11,640 ADS at a price raning from $1.22 per ADS to $1.28 per ADS. The Reporting Person also previously reported the total amount of securities beneficially owned following transaction as 35,860 and omitted the ADS acquired on January 10, 2025. The revised amount of securities beneficially owned following the transaction is 47,500 ADS. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:30 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantOrdinary Shares, par value $0.0001 per share | 1,720,000 | $0.00 | $1,032.00 |
DisclosureSEC source: 0000950170-25-002865 · ownership.xml · nonDerivative · entry 1 Gaslightwala Abizer · CIK 0002049375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,720,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. F2 · kind: On January 3, 2025, the Reporting Person acquired 1,720,000 Ordinary Shares at purchase prices ranging from of $0.00064 to $0.000625 per Ordinary Share. F2 · price: On January 3, 2025, the Reporting Person acquired 1,720,000 Ordinary Shares at purchase prices ranging from of $0.00064 to $0.000625 per Ordinary Share. Read SEC document |
| December 27, 2024 Filed Dec 30, 2024 21:30 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantOrdinary Shares, par value $0.0001 per share | 40,000,000 | $0.00 | $20,000.00 |
DisclosureSEC source: 0000950170-24-141158 · ownership.xml · nonDerivative · entry 1 Gaslightwala Abizer · CIK 0002049375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. F2 · kind: On December 27, 2024, the Reporting Person acquired 40,000,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share. F2 · price: On December 27, 2024, the Reporting Person acquired 40,000,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share. Read SEC document |
| December 26, 2024 Filed Dec 27, 2024 21:30 UTC | Akari Therapeutics Plc AKTX · Entity 7692 | GrantOrdinary Shares, par value $0.0001 per share | 30,000,000 | $0.00 | $15,000.00 |
DisclosureSEC source: 0000950170-24-140808 · ownership.xml · nonDerivative · entry 1 Gaslightwala Abizer · CIK 0002049375 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares. F2 · kind: On December 26, 2024, the Reporting Person acquired 30,000,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share. F2 · price: On December 26, 2024, the Reporting Person acquired 30,000,000 Ordinary Shares at a purchase price of $0.0005 per Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.